Singapore markets closed

NeuBase Therapeutics, Inc. (NBSE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0200+0.0600 (+6.25%)
At close: 04:00PM EDT
1.0600 +0.04 (+3.92%)
After hours: 06:12PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 32.58M
Enterprise value -56.74k
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.85
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.00

Trading information

Stock price history

Beta (5Y monthly) 0.77
52-week change 3-80.27%
S&P500 52-week change 3-1.04%
52-week high 35.5100
52-week low 30.8900
50-day moving average 31.4163
200-day moving average 32.4827

Share statistics

Avg vol (3-month) 384.83k
Avg vol (10-day) 357.78k
Shares outstanding 532.26M
Implied shares outstanding 6N/A
Float 828.04M
% held by insiders 18.69%
% held by institutions 137.61%
Shares short (12 May 2022) 4410.08k
Short ratio (12 May 2022) 45.03
Short % of float (12 May 2022) 41.29%
Short % of shares outstanding (12 May 2022) 41.27%
Shares short (prior month 13 Apr 2022) 4463k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 303 Feb 2019
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 303 Feb 2019

Financial highlights

Fiscal year

Fiscal year ends 29 Sept 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-54.47%
Return on equity (ttm)-107.81%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -32.62M
Net income avi to common (ttm)-33.47M
Diluted EPS (ttm)-1.0440
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)38.96M
Total cash per share (mrq)1.21
Total debt (mrq)6.32M
Total debt/equity (mrq)16.56
Current ratio (mrq)8.07
Book value per share (mrq)1.18

Cash flow statement

Operating cash flow (ttm)-25.03M
Levered free cash flow (ttm)-17.54M